Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:38:00.360Z.
Calculation as of: 2026-10-06T16:38:00.360Z.
Quote observation: 2026-10-06T16:35:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 85bde4aa0a662304b106d2bd805683c4a4a85ed0eecab472c1d88190f6ac555e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2025-08-12.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
PRICE/FCF RATIO AVG TTM
N/A
PRICE/FCF RATIO AVG 3Y
N/A
PRICE/FCF RATIO AVG 5Y
N/A
PRICE/FCF RATIO AVG 10Y
N/A
PRICE/FCF RATIO AVG 15Y
N/A
PRICE/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$1.44B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.43B
Price/FCF Ratio
79.39
TTM Avg
258.29
3Y Avg
258.29
5Y Avg
172.61
Market Cap
$1.46B
Price/FCF Ratio
9.65
TTM Avg
9.98
3Y Avg
22.18
5Y Avg
99.17
Market Cap
$1.41B
Price/FCF Ratio
54.42
TTM Avg
40.41
3Y Avg
45.21
5Y Avg
44.82
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | $1.45B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.46B | 23.65 | 16.96 | 29.77 | 40.80 |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 79.39 | 258.29 | 258.29 | 172.61 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 9.65 | 9.98 | 22.18 | 99.17 |
| The Pennant Group, Inc. (PNTG)vs › | $1.41B | 54.42 | 40.41 | 45.21 | 44.82 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.48B | N/A | N/A | N/A | N/A |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.48B | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/FCF RATIO |
|---|---|
| 2025-08-12 | 8.76 |
| 2025-08-11 | 8.59 |
| 2025-08-08 | 8.38 |
| 2025-08-07 | 8.49 |
| 2025-08-06 | 9.08 |
| 2025-08-05 | 9.25 |
| 2025-08-04 | 9.72 |
| 2025-08-01 | 9.50 |
| 2025-07-31 | 9.40 |
| 2025-07-30 | 9.88 |
| 2025-07-29 | 10.03 |
| 2025-07-28 | 10.43 |
| 2025-07-25 | 10.72 |
| 2025-07-24 | 10.49 |
| 2025-07-23 | 11.24 |
| 2025-07-22 | 10.80 |
| 2025-07-21 | 10.62 |
| 2025-07-18 | 11.33 |
| 2025-07-17 | 10.87 |
| 2025-07-16 | 10.36 |
| 2025-07-15 | 10.21 |
| 2025-07-14 | 10.03 |
| 2025-07-11 | 9.59 |
| 2025-07-10 | 9.97 |
| 2025-07-09 | 9.61 |
| 2025-07-08 | 9.60 |
| 2025-07-07 | 7.73 |
| 2025-07-03 | 7.33 |
| 2025-07-02 | 7.56 |
| 2025-07-01 | 7.43 |
| 2025-06-30 | 7.82 |
| 2025-06-27 | 7.73 |
| 2025-06-26 | 8.12 |
| 2025-06-25 | 7.27 |
| 2025-06-24 | 6.58 |
| 2025-06-23 | 6.84 |
| 2025-06-20 | 7.13 |
| 2025-06-18 | 7.18 |
| 2025-06-17 | 7.90 |
| 2025-06-16 | 8.48 |
| 2025-06-13 | 8.54 |
| 2025-06-12 | 8.64 |
| 2025-06-11 | 8.15 |
| 2025-06-10 | 8.20 |
| 2025-06-09 | 8.17 |
| 2025-06-06 | 8.24 |
| 2025-06-05 | 8.50 |
| 2025-06-04 | 8.84 |
| 2025-06-03 | 8.71 |
| 2025-06-02 | 7.71 |
| 2025-05-30 | 6.38 |
| 2025-05-29 | 7.76 |
| 2025-05-28 | 7.32 |
| 2025-05-27 | 7.14 |
| 2025-05-23 | 6.55 |
| 2025-05-22 | 6.48 |
| 2025-05-21 | 6.71 |
| 2025-05-20 | 6.44 |
| 2025-05-19 | 6.18 |
| 2025-05-16 | 5.90 |
| 2025-05-15 | 5.90 |
| 2025-05-14 | 5.30 |
| 2025-05-13 | 5.77 |
| 2025-05-12 | 5.93 |
| 2025-05-09 | 5.63 |
| 2025-05-08 | 5.87 |
| 2025-05-07 | 5.56 |
| 2025-05-06 | 5.33 |
| 2025-05-05 | 6.10 |
| 2025-05-02 | 6.35 |
| 2025-05-01 | 6.20 |
| 2025-04-30 | 5.42 |
| 2025-04-29 | 5.15 |
| 2025-04-28 | 4.91 |
| 2025-04-25 | 4.81 |
| 2025-04-24 | 4.51 |
| 2025-04-23 | 5.59 |
| 2025-04-22 | 5.77 |
| 2025-04-21 | 5.35 |
| 2025-04-17 | 4.92 |
| 2025-04-16 | 4.79 |
| 2025-04-15 | 4.74 |
| 2025-04-14 | 4.98 |
| 2025-04-11 | 4.58 |
| 2025-04-10 | 4.45 |
| 2025-04-09 | 4.67 |
| 2025-04-08 | 4.43 |
| 2025-04-07 | 5.22 |
| 2025-04-04 | 5.31 |
| 2025-04-03 | 5.46 |
| 2025-04-02 | 6.07 |
| 2025-04-01 | 5.80 |
| 2025-03-31 | 6.24 |
| 2025-03-28 | 6.48 |
| 2025-03-27 | 6.39 |
| 2025-03-26 | 6.10 |
| 2025-03-25 | 6.60 |
| 2025-03-24 | 6.73 |
| 2025-03-21 | 6.32 |
| 2025-03-20 | 6.78 |
| 2025-03-19 | 6.89 |
| 2025-03-18 | 6.84 |
| 2025-03-17 | 6.52 |
| 2025-03-14 | 6.23 |
| 2025-03-13 | 6.41 |
| 2025-03-12 | 6.41 |
| 2025-03-11 | 6.36 |
| 2025-03-10 | 6.68 |
| 2025-03-07 | 6.81 |
| 2025-03-06 | 6.65 |
| 2025-03-05 | 6.73 |
| 2025-03-04 | 6.72 |
| 2025-03-03 | 6.26 |
| 2025-02-28 | 6.94 |
| 2025-02-27 | 7.21 |
| 2025-02-26 | 6.64 |
| 2025-02-25 | 5.99 |
| 2025-02-24 | 6.14 |
| 2025-02-21 | 6.86 |
| 2025-02-20 | 6.90 |
| 2025-02-19 | 7.12 |
| 2025-02-18 | 7.25 |
| 2025-02-14 | 6.81 |
| 2025-02-13 | 6.42 |
| 2025-02-12 | 6.79 |
| 2025-02-11 | 7.07 |
| 2025-02-10 | 7.35 |
| 2025-02-07 | 7.59 |
| 2025-02-06 | 7.37 |
| 2025-02-05 | 7.28 |
| 2025-02-04 | 7.51 |
| 2025-02-03 | 8.51 |
| 2025-01-31 | 9.05 |
